US Biotech Sector Braces for Transformation as Trump Returns
Industry Analysis 2025: The US biotech sector is poised for significant transformation in 2025 under the second Trump administration, with regulatory shifts and market dynamics creating both opportunities and challenges for industry players. Regulatory Reset The Federal Trade Commission’s approach to merger control is expected to undergo substantial changes, marking a departure from the Biden administration’s stringent oversight. This shift is likely to catalyze M&A activity, particularly in the $5-15 billion transaction range. The appointment of Robert F. Kennedy Jr. as Secretary of Health and Human Services introduces uncertainty, particularly regarding vaccine development and pharmaceutical approvals. Market Growth Trajectory Despite political uncertainties, the global biotech market demonstrates robust growth potential, projected to expand from $483 billion in 2024 to $546 billion in 2025, representing a 13% increase. This growth is driven by technological advancements and sustained R&D investments across the…
